[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Fordyce EJ, Singh TP, Nash D, Gallagher B, Forlenza S: Survival rates in NYC in the era of combination ART. J Acquir Immune Defic Syndr; 2002 May 1;30(1):111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Since the advent of combined antiretroviral therapy in 1996, substantial decreases in HIV-related morbidity and mortality have been observed in the United States and other developed countries.
  • To assess the effects on overall survival and for specific AIDS-defining illnesses (ADIs), survival among persons with AIDS (PWAs) in New York City (NYC) before and after the introduction of combination therapy was investigated.
  • Improving survival for all ADIs was found among PWAs diagnosed after 1995, but changes for immunoblastic lymphoma, primary lymphoma of the brain, and invasive cervical cancer were only moderate and were statistically (p >.05) insignificant.
  • Burkitt lymphoma, immunoblastic lymphoma, invasive cervical cancer, and primary lymphoma of the brain had the highest RH of death among PWAs diagnosed after 1995.
  • [MeSH-major] AIDS-Related Opportunistic Infections / mortality. Acquired Immunodeficiency Syndrome / mortality. Anti-HIV Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. New York City / epidemiology. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12048371.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


2. Dawson MA, Schwarer AP, McLean C, Oei P, Campbell LJ, Wright E, Shortt J, Street AM: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica; 2007 Jan;92(1):e11-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
  • Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases.
  • To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand.
  • We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation.
  • It is also the first description of autologous stem cell transplantation in a patient with severe haemophilia A.
  • [MeSH-major] Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Genes, myc. Gingival Neoplasms / genetics. Hemophilia A / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Large-Cell, Immunoblastic / genetics. Peripheral Blood Stem Cell Transplantation. Translocation, Genetic
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / complications. Fatal Outcome. Humans. Male. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Transplantation, Autologous. Vincristine / administration & dosage


3. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN: Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist; 2010;15(3):293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals.
  • METHODS: An extensive literature search rendered 248 cases of PBL, from which 157 were HIV(+).
  • Seventy cases with HIV-associated PBL that received chemotherapy were identified.
  • In a univariate analysis, early clinical stage and a complete response to chemotherapy were associated with longer survival.
  • CONCLUSIONS: Patients with HIV-associated PBL have a poor prognosis.
  • Prognosis is strongly associated with achieving a complete clinical response to CHOP or CHOP-like chemotherapy.
  • Further research is needed to improve responses using novel therapeutic agents and strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(3):194 [10942339.001]
  • [Cites] J Hematol Oncol. 2009;2:47 [19909553.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1582-4 [12824797.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Haematologica. 2007 Jan;92(1):e11-2 [17405744.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Am J Hematol. 2007 Aug;82(8):761-5 [17094093.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]
  • [Cites] Intern Med. 2009;48(7):559-62 [19336959.001]
  • [Cites] Eur J Haematol. 2009 Jun;82(6):490-2 [19220417.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]
  • [Cites] AIDS. 2009 Sep 24;23(15):2029-37 [19531926.001]
  • [Cites] Am J Clin Pathol. 2009 Oct;132(4):597-605 [19762538.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • (PMID = 20167839.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC3227958
  •  go-up   go-down


Advertisement
4. Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M: A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Biotechnol Annu Rev; 2005;11:381-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.
  • Patients with aggressive histology HIV-related NHL who were previously untreated with chemotherapy, and who had no active opportunistic infection were eligible for the study.
  • Forty-seven patients were enrolled, most with diffuse large-cell or immunoblastic NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Bleomycin / adverse effects. Bleomycin / therapeutic use. CD4 Lymphocyte Count. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Injections, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Prospective Studies. Recombinant Proteins. Survival Analysis. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216784.001).
  • [ISSN] 1387-2656
  • [Journal-full-title] Biotechnology annual review
  • [ISO-abbreviation] Biotechnol Annu Rev
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


5. Boulanger E, Agbalika F, Maarek O, Daniel MT, Grollet L, Molina JM, Sigaux F, Oksenhendler E: A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J; 2001;2(3):172-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
  • INTRODUCTION: Primary effusion lymphoma is a rare type of B-cell lymphoproliferative disorder which is mainly observed in patients with HIV infection.
  • Lymphomatous cells bridge features of immunoblastic and anaplastic cells with a non-B non-T phenotype and are characterized by the presence of the human herpesvirus 8 genome.
  • PATIENTS AND METHODS: : Twelve HIV-infected patients with serous effusions containing large HHV8(+) lymphomatous cells were extensively evaluated to disclose associated visceral involvement.
  • RESULTS: Extraserous localizations of lymphoma were present in six cases (50%): mediastinal (n = 2), mesenteric (n = 2), pancreatic (n = 1), and bone marrow involvement (n = 1).
  • CONCLUSION: The clinical and molecular pattern, as well as the response to therapy suggest that primary effusion lymphoma represents an heterogenous type of virus-induced B-cell lymphoproliferative disorder, sharing pathophysiological features with that induced by the Epstein-Barr virus and occurring in immunocompromised patients.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920242.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8J337D1HZY / Cytosine; 8N3DW7272P / Cyclophosphamide; JIL713Q00N / cidofovir; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 37
  •  go-up   go-down


6. Ruff KR, Puetter A, Levy LS: Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer; 2007 Feb 26;7:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.
  • BACKGROUND: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.
  • Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque consequent to infection with simian immunodeficiency virus.
  • A recent study of SAIDS-NHL demonstrated a lymphoma-derived cell line to be sensitive to the growth inhibitory effects of the ubiquitous cytokine, transforming growth factor-beta (TGF-beta).
  • The authors concluded that TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis.
  • The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation.
  • Intracellular flow cytometry was used to analyze the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and distinguishing hallmarks of AIDS-NHL subclass.
  • Apoptosis was quantified by flow cytometric analysis of cell populations with sub-G1 DNA content and by measuring activated caspase-3.
  • RESULTS: Results confirmed the sensitivity of LCL8664, an immunoblastic SAIDS-NHL cell line, to TGF-beta1-mediated growth inhibition, and further demonstrated the partial rescue by simultaneous treatment with IL-6.
  • By comparison, human AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6.
  • Analysis of a recently derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-DLCBL.
  • CONCLUSION: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1477-85 [10555111.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23013-9 [10438468.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2500-10 [10946276.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):481-8 [10953968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4084-90 [11110677.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]
  • [Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3867-72 [12553006.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):661-8 [12740915.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]
  • [Cites] J Virol. 2004 Feb;78(4):1697-705 [14747535.001]
  • [Cites] Vet Pathol. 1988 Nov;25(6):456-67 [2850650.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10491-500 [15637055.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1615-22 [7478586.001]
  • [Cites] J Interferon Cytokine Res. 1995 Mar;15(3):261-8 [7584673.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):40-3 [8548771.001]
  • [Cites] Virology. 1995 Dec 20;214(2):431-8 [8553544.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Immunity. 1996 Nov;5(5):449-60 [8934572.001]
  • [Cites] Blood. 1997 Feb 1;89(3):941-7 [9028325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [9159168.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]
  • (PMID = 17324269.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074731; United States / NCI NIH HHS / CA / R01 CA74731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC1810304
  •  go-up   go-down


7. Engels EA, Pittaluga S, Whitby D, Rabkin C, Aoki Y, Jaffe ES, Goedert JJ: Immunoblastic lymphoma in persons with AIDS-associated Kaposi's sarcoma: a role for Kaposi's sarcoma-associated herpesvirus. Mod Pathol; 2003 May;16(5):424-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoblastic lymphoma in persons with AIDS-associated Kaposi's sarcoma: a role for Kaposi's sarcoma-associated herpesvirus.
  • Kaposi's sarcoma-associated herpesvirus, the viral agent of Kaposi's sarcoma, is associated with two lymphoproliferative disorders: primary effusion lymphoma and multicentric Castleman's disease.
  • To identify other lymphoproliferative conditions linked with Kaposi's sarcoma-associated herpesvirus, we studied non-Hodgkin's lymphomas arising in individuals with AIDS-associated Kaposi's sarcoma.
  • As expected, two primary effusion lymphomas were Kaposi's sarcoma-associated herpesvirus-positive, with immunohistochemistry demonstrating the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen in the nuclei of all neoplastic cells.
  • Additionally, three of seven evaluable cases of the immunoblastic variant of diffuse large B-cell lymphoma (immunoblastic lymphoma) showed similar latency-associated nuclear antigen staining.
  • These Kaposi's sarcoma-associated herpesvirus-positive immunoblastic lymphomas resembled primary effusion lymphoma histologically but were not known to involve body cavities (sites included lymph nodes, soft tissues of the neck, and spleen).
  • Notably, 5-20% of the neoplastic cells in the Kaposi's sarcoma-associated herpesvirus-positive immunoblastic lymphomas also showed cytoplasmic staining for viral interleukin-6, a biologically active cytokine homologue found in primary effusion lymphoma.
  • We conclude that Kaposi's sarcoma-associated herpesvirus is present in some immunoblastic lymphomas in persons with AIDS-associated Kaposi's sarcoma.
  • [MeSH-major] AIDS-Related Opportunistic Infections / etiology. Acquired Immunodeficiency Syndrome / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma, Large-Cell, Immunoblastic / etiology. Sarcoma, Kaposi / complications
  • [MeSH-minor] Antigens, Viral. Humans. Immunohistochemistry. Interleukin-6 / analysis. Viral Proteins / analysis


8. Oksenhendler E, Gerard L, Dubreuil ML, Levy Y, Matheron S, Cazals-Hatem D, Chevret S, Clauvel JP: Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Sep;39(1-2):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL).
  • Fifty two consecutive patients with HIV infection, aggressive NHL and CD4+ cells > or = 100 x 10(6)/l were included.
  • The median CD4 cell count was 276 x 10(6)/l.
  • Nineteen tumors were of the Burkitt's type, 23 were large cells, 7 immunoblastic, and 3 anaplastic.
  • Twenty-five patients had stage IV disease (bone marrow involvement in 7, and central nervous system in 9).
  • Achievement of complete remission was strongly associated with survival.
  • In conclusion, it seems that in HIV-infected patients with NHL and a CD4 cell count above 100 x 10(6)/l, high complete remission rate and prolonged survival can be achieved with the intensive LNHIV-91 regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Adult. Bleomycin / administration & dosage. Bleomycin / toxicity. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Drug Evaluation. Etoposide / administration & dosage. Etoposide / toxicity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Methotrexate / administration & dosage. Methotrexate / toxicity. Middle Aged. Prednisone / administration & dosage. Prednisone / toxicity. Recurrence. Survival Rate. Treatment Outcome. Vindesine / administration & dosage. Vindesine / toxicity

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975387.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol
  •  go-up   go-down


9. Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill PS, Levine AM: Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res; 2002 Feb;26(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
  • P-glycoprotein is a product of the multidrug resistance (MDR-1) gene.
  • In non-Hodgkin's lymphoma, less than 20% of untreated de novo lymphomas express MDR-1 compared with approximately 50% after failure of chemotherapy.
  • We wished to study the expression of MDR-1 in AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).
  • Tissue biopsies from 50 patients with newly diagnosed AIDS-NHL were studied by immunohistochemical analysis using C494, a monoclonal antibody specific for the MDR-1 isoform of P-gp.
  • MDR-1 expression was correlated with patient demographics, lymphoma characteristics, response to chemotherapy, and survival.
  • A prior AIDS-defining opportunistic infection was reported in 35 patients (70%).
  • Thirty-two patients (63%) had received prior anti-HIV therapy, including a protease inhibitor in five (10%).
  • Pathologic types consisted of diffuse large cell in 13 (26%), immunoblastic in 13 (26%), small non-cleaved in 22 (44%), and high grade not otherwise specified in two (4%).
  • The majority of patients (76%) had stage III/IV disease.
  • Pre-treatment lymphoma tissues from 33 patients (66%) stained positively for MDR-1.
  • Strategies to overcome MDR-1 expression may be important for initial treatment in patients with AIDS-NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / metabolism. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Lymphoma, AIDS-Related / metabolism. Neoplasm Proteins / biosynthesis. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / mortality. Adult. Anti-HIV Agents / therapeutic use. Bleomycin / administration & dosage. Bleomycin / metabolism. Bleomycin / pharmacology. Cyclophosphamide / administration & dosage. Cyclophosphamide / metabolism. Cyclophosphamide / pharmacology. Dexamethasone / administration & dosage. Dexamethasone / metabolism. Dexamethasone / pharmacology. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / metabolism. Doxorubicin / pharmacology. Female. Humans. Leucovorin / administration & dosage. Leucovorin / metabolism. Leucovorin / pharmacology. Male. Methotrexate / administration & dosage. Methotrexate / metabolism. Methotrexate / pharmacology. Middle Aged. Prednisone / administration & dosage. Prednisone / metabolism. Prednisone / pharmacology. Remission Induction. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage. Vincristine / metabolism. Vincristine / pharmacology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11755462.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol
  •  go-up   go-down


10. Markasz L, Stuber G, Flaberg E, Jernberg AG, Eksborg S, Olah E, Skribek H, Szekely L: Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer; 2006;6:265
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
  • BACKGROUND: Epstein-Barr virus (EBV) is the causative agent of immunosuppression associated lymphoproliferations such as post-transplant lymphoproliferative disorder (PTLD), AIDS related immunoblastic lymphomas (ARL) and immunoblastic lymphomas in X-linked lymphoproliferative syndrome (XLP).
  • Reducing the immunosuppression in recipients of solid organ transplants (SOT) or using highly active antiretroviral therapy in AIDS patients leads to complete remission in 23-50% of the PTLD/ARL cases but will not suffice for recipients of bone marrow grafts.
  • Chemotherapy is used for the non-responding cases only as the second or third line of treatment.
  • The most frequently used chemotherapy regimens originate from the non-Hodgkin lymphoma protocols and there are no cytotoxic drugs that have been specifically selected against EBV induced lymphoproliferative disorders.
  • METHODS: As lymphoblastoid cell lines (LCLs) are well established in vitro models for PTLD, we have assessed 17 LCLs for cytotoxic drug sensitivity.
  • After three days of incubation, live and dead cells were differentially stained using fluorescent dyes.
  • The precise numbers of live and dead cells were determined using a custom designed automated laser confocal fluorescent microscope.
  • RESULTS: Independently of their origin, LCLs showed very similar drug sensitivity patterns against 29 frequently used cytostatic drugs.
  • [MeSH-major] Antineoplastic Agents / toxicity. Antiviral Agents / pharmacology. B-Lymphocytes / virology. Cell Transformation, Viral. Herpesvirus 4, Human / physiology. Lymphoma / drug therapy. Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Bone Marrow Transplantation / adverse effects. Cell Line, Tumor. Humans. Postoperative Complications / immunology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):653-8 [9533533.001]
  • [Cites] Am J Clin Pathol. 1997 Apr;107(4):419-29 [9124210.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):69-75 [9918204.001]
  • [Cites] Bone Marrow Transplant. 1999 Feb;23(3):251-8 [10084256.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2208-16 [10498590.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1805-9 [15550586.001]
  • [Cites] Am J Transplant. 2005 Mar;5(3):566-72 [15707412.001]
  • [Cites] Biol Pharm Bull. 2005 Jul;28(7):1202-7 [15997098.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5893-9 [16115931.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]
  • [Cites] Eur J Pharm Sci. 2006 Jan;27(1):54-61 [16183265.001]
  • [Cites] Anticancer Drugs. 2006 Apr;17(4):411-5 [16549998.001]
  • [Cites] Blood. 2000 Feb 1;95(3):807-14 [10648390.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:113-6 [10707791.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1205-18 [10778943.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jun;44(6):1697-700 [10817732.001]
  • [Cites] Haematologica. 2002 Jan;87(1):67-77 [11801467.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):919-27 [12123338.001]
  • [Cites] Ther Drug Monit. 2002 Aug;24(4):502-6 [12142634.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1810-8 [12419756.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Sep;15(3):517-32 [12468403.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):35-40 [12506167.001]
  • [Cites] Pediatr Transplant. 2003;7 Suppl 3:44-50 [12603692.001]
  • [Cites] J Clin Pharmacol. 2003 Sep;43(9):1003-7 [12971033.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1724-33 [15073863.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3361-4 [15150084.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2108-21 [15169797.001]
  • [Cites] Pharmacol Res. 2004 Aug;50(2):173-9 [15177306.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4724-33 [15269145.001]
  • [Cites] Cancer. 1977 Dec;40(6):2772-8 [73408.001]
  • [Cites] Br J Cancer. 1980 Apr;41(4):644-7 [6155927.001]
  • [Cites] J Clin Pharmacol. 1981 Feb-Mar;21(2):72-8 [7229120.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;8(2):211-4 [6125275.001]
  • [Cites] J Neurooncol. 1983;1(2):139-44 [6678966.001]
  • [Cites] Blood. 1988 Aug;72(2):520-9 [2840986.001]
  • [Cites] Eur J Clin Pharmacol. 1989;36(3):265-71 [2526020.001]
  • [Cites] Pediatr Nephrol. 1990 Sep;4(5):470-3 [2242307.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):147-58 [1845872.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;29(1):66-70 [1742851.001]
  • [Cites] J Heart Lung Transplant. 1991 Nov-Dec;10(6):877-86; discussion 886-7 [1661607.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(3):173-7 [1733548.001]
  • [Cites] Scand J Infect Dis Suppl. 1991;80:94-104 [1666450.001]
  • [Cites] Cancer Surv. 1992;13:53-80 [1330300.001]
  • [Cites] Ann N Y Acad Sci. 1993 Aug 12;690:86-100 [7690218.001]
  • [Cites] Trends Microbiol. 1994 Apr;2(4):125-30 [8012755.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):191-9 [7799020.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):961-8 [7707124.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(4):345-51 [7628055.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(5):429-34 [8599865.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1215-28 [8642263.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):891-9 [9815764.001]
  • (PMID = 17101045.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents
  • [Other-IDs] NLM/ PMC1664586
  •  go-up   go-down


11. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF: HIV-associated lymphomas and gamma-herpesviruses. Blood; 2009 Feb 5;113(6):1213-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated lymphomas and gamma-herpesviruses.
  • Among the most common HIV-associated lymphomas are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with immunoblastic-plasmacytoid differentiation (also involving the central nervous system).
  • Lymphomas occurring specifically in HIV-positive patients include primary effusion lymphoma (PEL) and its solid variants, plasmablastic lymphoma of the oral cavity type and large B-cell lymphoma arising in Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease.
  • These lymphomas together with BL and DLBCL with immunoblastic-plasmacytoid differentiation frequently carry EBV infection and display a phenotype related to plasma cells.
  • EBV infection occurs at different rates in different lymphoma types, whereas KSHV is specifically associated with PEL, which usually occurs in the setting of profound immunosuppression.
  • The current knowledge about HIV-associated lymphomas can be summarized in the following key points:.
  • (1) lymphomas specifically occurring in patients with HIV infection are closely linked to other viral diseases;.
  • (2) AIDS lymphomas fall in a spectrum of B-cell differentiation where those associated with EBV or KSHV commonly exhibit plasmablastic differentiation; and (3) prognosis for patients with lymphomas and concomitant HIV infection could be improved using better combined chemotherapy protocols incorporating anticancer treatments and antiretroviral drugs.
  • [MeSH-major] Gammaherpesvirinae / pathogenicity. HIV-1 / pathogenicity. Herpesviridae Infections / virology. Lymphoma, AIDS-Related / virology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Humans. Tumor Virus Infections / pathology. Tumor Virus Infections / therapy. Tumor Virus Infections / virology


12. Tarantul V, Nikolaev A, Hannig H, Kalmyrzaev B, Muchoyan I, Maximov V, Nenasheva V, Dubovaya V, Hunsmann G, Bodemer W: Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus-associated non-Hodgkin's lymphoma. Neoplasia; 2001 Mar-Apr;3(2):132-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus-associated non-Hodgkin's lymphoma.
  • Several novel, differentially transcribed genes were identified in one centroblastic and one immunoblastic HIV-associated B-cell non-Hodgkin's lymphoma (B-NHL) by subtractive cloning.
  • The data obtained on upregulated expression of the genes in human B-NHL of HIV-infected patients considerably overlap with those obtained earlier for the B-NHL of simian immunodeficiency virus-infected monkeys.
  • In the centroblastic lymphoma, one transcript revealed a fusion of the 3'-untranslated region of the set gene and the C-terminal region of the IgL gene.
  • The expected amplification product was obtained in both cases pointing to a genomic rearrangement.
  • The IgL-set fusion sequence was not found in cDNA preparations and genomic DNA of the immunoblastic HIV-associated B-NHL.
  • Further studies are necessary to determine whether these genes contribute to lymphoma development or can be used as therapeutic targets.
  • [MeSH-major] Lymphoma, AIDS-Related / metabolism. Lymphoma, Non-Hodgkin / virology. RNA, Messenger / metabolism. Transcription, Genetic
  • [MeSH-minor] 3' Untranslated Regions. Base Sequence. Blotting, Northern. Blotting, Southern. Cloning, Molecular. DNA, Complementary / metabolism. Databases, Factual. Dose-Response Relationship, Drug. Humans. Immunoblotting. Immunoglobulins / metabolism. Lymphoma / metabolism. Molecular Sequence Data. Polymerase Chain Reaction. Sequence Homology, Nucleic Acid. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]
  • [Cites] Nucleic Acids Res. 1989 Apr 25;17(8):2919-32 [2471144.001]
  • [Cites] Virology. 1992 Oct;190(2):856-60 [1381540.001]
  • [Cites] Science. 1993 Feb 12;259(5097):946-51 [8438152.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5569-75 [8221699.001]
  • [Cites] FEBS Lett. 1994 Mar 7;340(3):231-5 [8131851.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] Science. 1995 Jan 20;267(5196):316-7 [7824924.001]
  • [Cites] Leukemia. 1995 Mar;9(3):480-500 [7885046.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1833-40 [7753558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4279-83 [7753797.001]
  • [Cites] J Biol Chem. 1995 Jun 23;270(25):14891-8 [7797467.001]
  • [Cites] J Biol Chem. 1995 Jul 21;270(29):17423-8 [7615547.001]
  • [Cites] Acta Haematol. 1996;95(3-4):193-8 [8677742.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1198-208 [8684002.001]
  • [Cites] Blood. 1996 Jul 15;88(2):674-81 [8695815.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):911-20 [8703825.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3634-7 [8705997.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):160-5 [9212238.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Oct;20(2):113-9 [9331562.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]
  • [Cites] Pathol Res Pract. 1998;194(2):87-95 [9584321.001]
  • [Cites] J Pathol. 1999 Jun;188(2):133-8 [10398155.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1747-54 [10477700.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3567-75 [10552968.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):173-9 [10659056.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 [271968.001]
  • [Cites] Eur J Biochem. 1985 Dec 2;153(2):367-71 [3935435.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 May;84(9):2824-8 [3033665.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Mar 31;159(3):1100-6 [2539139.001]
  • [Cites] Mol Cell Biol. 1992 Aug;12(8):3346-55 [1630450.001]
  • (PMID = 11420749.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / DNA, Complementary; 0 / Immunoglobulins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1505419
  •  go-up   go-down


13. Dal Maso L, Rezza G, Zambon P, Tagliabue G, Crocetti E, Vercelli M, Zanetti R, Falcini F, Tonini G, Mangone L, De Lisi V, Ferretti S, Tumino R, Stanta G, Vitarelli S, Serraino D, Franceschi S, Cancer and AIDS Registry Linkage Study: Non-Hodgkin lymphoma among young adults with and without AIDS in Italy. Int J Cancer; 2001 Aug 1;93(3):430-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma among young adults with and without AIDS in Italy.
  • To compare the presentation and prognosis of non-Hodgkin lymphoma (NHL) in people with AIDS (PWA) and in the general Italian population, a record linkage study was carried out.
  • The fraction of NHLs attributable to HIV/AIDS was also estimated.
  • Information from the National AIDS Registry (RAIDS) was linked with records from 13 cancer registries (CR), covering about 15% of the Italian population.
  • During the period 1985--94, among PWA ages 15--49, 136 NHLs were identified (8% of all NHLs) and were compared with 1,481 concurrent incident NHL cases of the same age group among non-PWA.
  • Percentages above 13% of all NHLs were registered in the northern areas of Genoa and Varese, i.e., the most heavily affected by the AIDS epidemic.
  • Between 1 year prior to and 3.5 years after AIDS diagnosis, PWA showed an overall standardised incidence ratio (SIR) for NHL of 302.
  • SIR was particularly high (394) within 3 months after AIDS diagnosis and subsequently declined to 170.
  • SIR was somewhat higher in females (428) than in males (280) but similar among intravenous-drug users (299) and other HIV-transmission groups (309).
  • High-grade NHL, particularly immunoblastic and Burkitt's lymphoma, were twice as frequent among PWA than non-PWA.
  • Except for the high proportion of brain localisation, no clear difference emerged in the pattern of NHL presentation site in PWA compared with non-PWA.
  • At variance with NHL in the general population, among PWA histological grade had little impact on survival, which overall appeared to be very poor (2-year survival: 10%; 95% confidence interval: 3%--17%).
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Public Health / statistics & numerical data

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11433410.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement